Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baron B, Krivoshik A, Hirmand M, Smith MR. Tombal B, et al. Among authors: braeckman j. J Urol. 2018 Feb;199(2):459-464. doi: 10.1016/j.juro.2017.08.103. Epub 2017 Sep 1. J Urol. 2018. PMID: 28867562 Clinical Trial.
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Baron B, Hirmand M, Smith MR. Tombal B, et al. Among authors: braeckman j. Eur Urol. 2015 Nov;68(5):787-94. doi: 10.1016/j.eururo.2015.01.027. Epub 2015 Feb 14. Eur Urol. 2015. PMID: 25687533 Free article. Clinical Trial.
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Tombal B, et al. Among authors: braeckman j. Lancet Oncol. 2014 May;15(6):592-600. doi: 10.1016/S1470-2045(14)70129-9. Epub 2014 Apr 14. Lancet Oncol. 2014. PMID: 24739897 Clinical Trial.
Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium.
Goossens ME, Buntinx F, Joniau S, Ackaert K, Ameye F, Billiet I, Braeckman J, Breugelmans A, Darras J, Dilen K, Goeman L, Kellen E, Tombal B, Van Bruwaene S, Van Cleyenbreuge B, Van der Aa F, Vekemans K, Van Poppel H, Zeegers MP. Goossens ME, et al. Among authors: braeckman j. BMC Urol. 2012 Mar 21;12:8. doi: 10.1186/1471-2490-12-8. BMC Urol. 2012. PMID: 22436453 Free PMC article. Clinical Trial.
Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial.
Goossens ME, Zeegers MP, van Poppel H, Joniau S, Ackaert K, Ameye F, Billiet I, Braeckman J, Breugelmans A, Darras J, Dilen K, Goeman L, Tombal B, Van Bruwaene S, Van Cleyenbreugel B, Van der Aa F, Vekemans K, Buntinx F. Goossens ME, et al. Among authors: braeckman j. Eur J Cancer. 2016 Dec;69:9-18. doi: 10.1016/j.ejca.2016.09.021. Epub 2016 Oct 29. Eur J Cancer. 2016. PMID: 27814472 Clinical Trial.
Prostate HistoScanning: a screening tool for prostate cancer?
De Coninck V, Braeckman J, Michielsen D. De Coninck V, et al. Among authors: braeckman j. Int J Urol. 2013 Dec;20(12):1184-90. doi: 10.1111/iju.12148. Epub 2013 Apr 17. Int J Urol. 2013. PMID: 23594146 Clinical Trial.
Prognostic factors in prostate cancer.
Braeckman J, Michielsen D. Braeckman J, et al. Recent Results Cancer Res. 2007;175:25-32. doi: 10.1007/978-3-540-40901-4_3. Recent Results Cancer Res. 2007. PMID: 17432552 Review.
84 results